Trial registration. Controlled-Trials.com ISRCTN43070564
I.M. Lang, R. Badr-Eslam, N. Greenlaw, R. Young, and P.G. Steg are CLARIFY investigators.
The population of patients with established coronary artery disease (CAD) is growing because of an improvement in outcomes and survival from acute disease episodes. Nevertheless, these patients remain at high risk of cardiovascular events. Thus, CAD management is important in prevention of disease progression. The objective of this analysis was to describe disease management and clinical outcome of Austrian outpatients with stable CAD over 5 years by using data from the international CLARIFY registry.
CLARIFY was an international prospective observational registry of outpatients with stable CAD, defined as prior myocardial infarction or revascularization (CABG or PCI), coronary stenosis of more than 50% by coronary angiography or chest pain with myocardial ischemia. We analyzed demographic characteristics, risk factors, treatments and clinical outcomes of 424 Austrian outpatients with established CAD who were enrolled between November 2009 and July 2010 and observed until September 2015.
The primary risk factors in Austrian outpatients with stable CAD were smoking (current smokers: 13.2%), overweight (77.1%), hypertension (78.5%), raised low-density lipoprotein (LDL) cholesterol plasma levels (81.4% ≥ 0.7 g/l or 1.8 mmol/l), elevated heart rate (≥70 bpm: 60.9% in patients with anginal symptoms) and poor physical activity (none or light activity: 63.4%). Patients received lipid-lowering drugs (predominantly statins), aspirin, beta-blockers and angiotensin-converting enzyme (ACE) inhibitors according to current recommendations. After 5 years a systolic blood pressure (SBP) < 140 mm Hg and diastolic blood pressure (DBP) < 90 mm Hg was reached in 58.5% of patients. Of the patients 70.4% had LDL cholesterol plasma levels below 1.0 g/l (2.6 mmol/l), 42.1% of smokers had stopped smoking, 42.9% of patients with anginal symptoms had a heart rate ≤60 bpm and 26.0% of diabetic patients had brought their HbA1c levels below 6.5%. Cardiovascular death, myocardial infarction or stroke occurred in 30 patients (7.1%), all-cause death in 25 cases (5.9%) and cardiovascular death in 15 cases (3.5%). Myocardial infarction was reported in 14 patients (fatal and non-fatal: 3.3%) and stroke in 8 patients (fatal and non-fatal: 1.9%), 39 patients (9.2%) underwent myocardial revascularization and 124 patients (29.2%) experienced cardiovascular hospitalization.
Characteristics of Austrian outpatients with stable CAD corresponded to those of patients with CAD in other developed countries. Medical treatments following the recommendations of the European guidelines were prescribed in the majority of patients; however, recommended goals of life style interventions including a heart rate less than 60 bpm and general risk factor management were not achieved by a high proportion of patients. Heart rate control and life style changes remain unmet needs of cardiovascular care in Austria.
WHO. The global burden of disease: 2004 update. 2004. www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html. Accessed: 26. Jul 2016.
Steg G, on behalf of the BEAUTIFUL Executive Committee, editors. The CLARIFY registry: management of stable coronary artery disease in clinical practice. Brochure for participating doctors. 2009.
Steg PG, Glreenlaw N, Tendera M, Tardif JC, Ferrari R, Al-Zaibag M, Dorian P, Hu D, Shalnova S, Sokn FJ, Ford I, Fox KM, for the CLARIFY Investigators. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease. Data from the international observational CLARIFY registry. JAMA Intern Med. 2014;174(10):1651–9. CrossRefPubMed
Tunstall-Pedeo H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel P, for the WHO MONICA (monitoring trends and determinants in cardiovascular disease) Project. Contribution of trends in survival and coronary event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Lancet. 1999;353:1547–57. CrossRef
Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary disease: randomised, double-blind, placebo-controlled multicentre trial (the EUROPA study). Lancet. 2003;362:782–8. CrossRefPubMed
Alcocer-Gamba MA, Martinez-Sanchez C, Verdejo-Paris J, Ferrari R, Fox K, Greenlaw N, Steg PG, for the CLARIFY investigators. Heart rate and use of β‑blockers in Mexican stable outpatients with coronary artery disease. Arch Cardiol Mex. 2015;85(4):270–7. PubMed
Steg PG. Heart rate management in coronary artery disease: the CLARIFY registry. Eur Heart J. 2009;11(Suppl D):D13–D8. CrossRef
Erglis A, Mintale I, Latkovskis G, Balode I, Jegere S, Bajare I, Rozenbergs A, Greenlaw N, Ferrari R, Steg PG, for the CLARIFY registry investigators. Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europa and globally: analysis of the CLARIFY registry. Medicina (B Aires). 2015;51:240–6. CrossRef
R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014. http://www.R-project.org/.
EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II euro heart survey programme. Eur Heart J. 2001;22:554–72. CrossRef
Daly CA, Clemes F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM, on behalf of the Euro Heart Survey investigators. The initial management of stable angina in Europe, from the Euro Heart Survey. A description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of stable angina. Eur Heart J. 2005;26:1011–22. CrossRefPubMed
Steg PG, Greenlaw N, Tardif JC, Tendera M, Ford I, Kääb S, Abergel H, Fox KM, Ferrari R, on behalf of the CLARIFY registry investigators. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J. 2012;33:2831–40. CrossRefPubMedPubMedCentral
Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJM. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34:2949–3003. CrossRefPubMed
Pflieger M, Winslow BT, Mills K, Dauber IM. Medical management of stable coronary artery disease. Am Fam Physician. 2011;83:819–26. PubMed
Daly CA, Clemes F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM, on behalf of the Euro Heart Survey investigators. The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of stable angina. Eur Heart J. 2005;26:996–1010. CrossRefPubMed
Erglis A, Mintale I, Latkovskis G, Balode I, Jegere S, Bajare I, Rozenbergs A, Greenlaw N, Ferrari R, Steg PG, for the CLARIFY registry investigators. Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: analysis of the CLARIFY registry. Medicina (B Aires). 2015;51:240–6. CrossRef
Lerner A, Kannel W. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26 year follow-up of the Framingham population. Am Heart J. 1985;111:383–90. CrossRef
Kotseva K, Wood D, De Backer G, De Bacquer D, Pyöräläc K, Keil U, EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Prev Cardiol. 2009;16:121–37. CrossRef
IARC. Reversal of risk after quitting smoking. IARC Handbooks of Cancer Prevention, Tobacco control, vol 11. Lyon, Geneva: IARC, World Health Organization; 2007.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. CrossRef
SPRINT Research Group, Wright JT Jr., Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16. CrossRef
Vidal-Tetiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, Tendera M, Tavazzi L, Bhatt DL, Steg PG, for the CLARIFY investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388(10056):2142–52. doi: 10.1016/s0140-6736(16)31326-5. CrossRef
Fraker TD, Fihn SD, writing on behalf of the 2002 chronic stable angina writing committee. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation. 2007;116:2762–72. published correction appears in Circulation 2007;116:e558. CrossRefPubMed
CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39. CrossRef
Hochmann JS, Steg PG. Does preventive PCI work? N Engl J Med. 2007;356:1572–4. CrossRef
Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GBJ, Weintraub WS, for the COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16. CrossRefPubMed
Daly CA, De Stavola B, Lopez-Sendon JL, Tavazzi L, Boersma E, Clemens F, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM, on behalf of the Euro Heart Survey investigators. Predicting prognosis in stable angina – results from the Euro Heart Survey of stable angina: prospective observational study. BMJ. 2006;332:262–7. CrossRefPubMedPubMedCentral
Management and clinical outcome of stable coronary artery disease in Austria
Results from 5 years of the CLARIFY registry
Irene M. Lang
Philippe Gabriel Steg
- Springer Vienna
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II